Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could exercise retrain the heart in long COVID?

NCT ID NCT05530317

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial tests whether a structured cardiac rehabilitation program can improve exercise capacity and heart rate response in people with Long COVID. Participants have persistent symptoms and reduced exercise tolerance after a confirmed COVID-19 infection. The program includes personalized exercise prescriptions based on baseline testing, with careful attention to avoid post-exertional malaise. The study measures changes in peak oxygen uptake and heart rate reserve, along with symptoms and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cardiac rehabilitation, including tailored exercise prescriptions and resistance training
What this could lead to
If effective, cardiac rehabilitation could become a standard therapy to improve exercise tolerance and heart rate response in people with Long COVID.
What could go wrong
This is a small proof-of-concept trial, so results may not apply broadly. Exercise must be carefully tailored to avoid post-exertional malaise, a common Long COVID symptom.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

13 people

The number who actually took part.

Started

Dec 2022

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or older 2. Previously documented SARS-CoV-2 RNA positivity from an oral or nasal swab, as measured by a nucleic acid amplification test, documented positive antigen testing, or positive nucleocapsid antibody. Documentation of the positive test is required. 3. Presence of persistent symptoms, defined as at least one COVID-attributed symptom newly present during acute illness or worse than baseline and reported to still be present for at least 90 days following symptom onset. This will be ascertained using study case report forms. 4. Reduced exercise capacity \<100% predicted or self-reported reduction in exercise capacity compared to pre-COVID. 5. Willing and able to actively participate in cardiac rehabilitation including attending at least 12 in person sessions at UCSF Parnassus (intervention arm only). 6. Agree to participate in the LIINC Study including the cardiovascular substudy if they are not already participating. Exclusion Criteria: 1. Pregnant or intention to become pregnant during study 2. Pre-existing congenital heart disease, heart failure, pulmonary hypertension, heart or lung transplant, or cardiac valve surgery 3. Myocardial infarction, or coronary artery bypass graft surgery, or new diagnosis of heart failure with a reduced ejection fraction \<40% within 90 days prior to enrollment (Class I indications for cardiac rehabilitation) 4. Acute myocarditis diagnosed \<90 days prior 5. Atrial fibrillation, atrial flutter, or other arrhythmias requiring antiarrhythmic therapy 6. Use of beta-blockers, non-dihydropyridine calcium channel blockers or ivabradine 7. Implanted pacemaker or defibrillator 8. Chronic lung disease requiring the use of home oxygen therapy 9. Inability to ride a sitting bicycle for CPET 10. Severe post-exertional malaise or symptom worsening that would preclude participation in cardiac rehabilitation 11. Medical or psychological comorbidities that would prevent safe participation in the trial, in the opinion of the Principal Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, San Francisco

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.